HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges.
Sabrina A AssoumouSamantha M PaniaguaPriscilla GonzalezJianing WangCurt G BeckwithLaura F WhiteJessica L TaylorKristen CooganJeffrey H SametBenjamin P LinasPublished in: AIDS and behavior (2021)
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) and buprenorphine decrease HIV acquisition. Between November, 2016 and July, 2017, we surveyed persons (N = 200) at a drug detoxification center to assess their interest in PrEP and in buprenorphine, and to examine factors associated with such interests. Over the previous 6 months, 58% (117/200) injected drugs, 87% (173/200) used opioids, 50% (85/171) had condomless sex. Only 22% (26/117) of persons who injected drugs were aware of PrEP, yet 74% (86/116) and 72% (84/116) were interested in oral or injectable PrEP, respectively. Thirty-eight percent (47/125) of persons not receiving buprenorphine or methadone expressed interest in buprenorphine. After multivariable adjustment, Latinx ethnicity was associated with interest in PrEP (aOR 3.80; 95% CI 1.37-10.53), while male gender (aOR 2.76; 95% CI 1.21-6.34) was associated with interest in buprenorphine. Opportunities exist to implement PrEP and buprenorphine within drug detoxification centers.Clinical trial registration NCT02869776. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02869776?term=Sabrina+Assoumou&cond=HIV+HCV&rank=1 .
Keyphrases
- men who have sex with men
- hiv testing
- hiv positive
- human immunodeficiency virus
- antiretroviral therapy
- hepatitis c virus
- hiv infected
- clinical trial
- chronic pain
- hiv aids
- computed tomography
- pain management
- drug induced
- randomized controlled trial
- preterm infants
- south africa
- phase ii
- contrast enhanced
- hyaluronic acid
- preterm birth
- double blind